Maravai LifeSciences Holdings, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.4M | $65.8M | $49.9M | $41.6M | $47.4M | $46.9M | $56.6M | $69.0M |
| Cost of Revenue | $30.8M | $32.1M | $37.0M | $36.0M | $39.6M | $39.1M | $37.2M | $36.8M |
| Gross Profit | $20.7M | $33.7M | $12.8M | $5.7M | $7.8M | $7.7M | $19.4M | $32.2M |
| Gross Margin | 40.1% | 51.2% | 25.8% | 13.6% | 16.4% | 16.5% | 34.3% | 46.7% |
| Operating Expenses | ||||||||
| Research & Development | $3.7M | $3.9M | $3.8M | $3.8M | $4.9M | $4.9M | $4.6M | $4.7M |
| SG&A Expense | $32.1M | $29.1M | $31.4M | $35.4M | $38.7M | $39.6M | $41.2M | $39.1M |
| Operating Income | $-15.1M | $-2.2M | $-58.8M | $-41.0M | $-66.3M | $-49.2M | $-37.7M | $-165.6M |
| Operating Margin | -29.3% | -3.3% | -117.9% | -98.6% | -139.8% | -104.9% | -66.7% | -239.9% |
| Interest Expense | — | — | — | — | — | — | — | $13.6M |
| Pretax Income | $-21.8M | $-6.5M | $-63.0M | $-45.1M | $-74.1M | $-52.7M | $-46.1M | $-172.1M |
| Income Tax Expense | $-171.0K | $-151.0K | $6.0K | $-92.0K | $-4.3M | $162.0K | $-7.0K | $311.0K |
| Net Income | $-12.4M | $-3.7M | $-35.7M | $-25.6M | $-39.6M | $-29.9M | $-25.9M | $-97.1M |
| Net Margin | -24.1% | -5.7% | -71.6% | -61.4% | -83.5% | -63.9% | -45.8% | -140.6% |
| EPS (Basic) | $-0.08 | $-0.02 | $-0.24 | $-0.18 | $-0.27 | $-0.21 | $-0.21 | $-0.68 |
| EPS (Diluted) | $-0.08 | $-0.02 | $-0.24 | $-0.18 | $-0.27 | $-0.21 | $-0.21 | $-0.68 |
| Shares Outstanding (Basic) | 148.0M | 146.4M | 144.4M | 144.7M | 144.2M | 143.4M | 137.9M | 141.6M |
| Shares Outstanding (Diluted) | 148.0M | 146.4M | 144.4M | 144.7M | 144.2M | 143.4M | 137.9M | 141.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |